NCT05053971
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1; Patients must have received at least one standard of care regimen for metastatic disease
Exclusions: Patients with known untreated or symptomatic brain or leptomeningeal metastases; Patients with prior exposure to ZEN003694, HDAC inhibitors, or investigational BET inhibitors
https://ClinicalTrials.gov/show/NCT05053971